SCHEMBL20534343

SCHEMBL20534343

CSc1ccc(C(=O)[C](C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.55
LMNA P02545 3/20 0.46
HPGD P15428 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HAO1 Q9UJM8 1/20 0.44
ALDH1A1 P00352 5/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
RAB9A P51151 2/20 0.43
KMT2A Q03164 2/20 0.43
NFKB1 P19838 2/20 0.43
TSHR P16473 2/20 0.43
GAA P10253 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5859663 0.88 PLK1 (0.61) PLK1LMNAHPGDL3MBTL1HAO1
SCHEMBL10110528 0.82 PLK1 (0.55) PLK1LMNAHPGDL3MBTL1HAO1
SCHEMBL195321 0.81 HPGD (0.70) PLK1LMNAHPGDL3MBTL1HAO1
SCHEMBL7090547 0.80 CES2 (0.65) PLK1LMNAHPGDHAO1ALDH1A1
SCHEMBL31626735 0.80 PLK1 (0.53) PLK1LMNAHPGDL3MBTL1HAO1
SCHEMBL7089334 0.80 CES2 (0.70) PLK1LMNAHPGDHAO1ALDH1A1
SCHEMBL11384642 0.79 MAPT (0.49) PLK1LMNAHPGDL3MBTL1HAO1
SCHEMBL11384640 0.79 MAPT (0.49) PLK1LMNAHPGDL3MBTL1HAO1
SCHEMBL31626804 0.78 PLK1 (0.52) PLK1LMNAHPGDL3MBTL1HAO1
SCHEMBL6050656 0.78 CES2 (0.67) PLK1LMNAHAO1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110914250-B Novel process for synthesizing tilobaxib 珂思玛股份公司 2023-06-27 CN claimed
EP-3609877-B1 PROCESS FOR THE SYNTHESIS OF FIROCOXIB COSMA S P A (IT) 2020-12-23 EP claimed
US-10807962-B2 Process for the synthesis of firocoxib COSMA S.P.A. (IT) 2020-10-20 US claimed
US-20200102279-A1 NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB COSMA S.P.A. (IT) 2020-04-02 US claimed
CN-110914250-A Novel process for synthesizing felicoxib 珂思玛股份公司 2020-03-24 CN claimed
EP-3609877-A1 NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB Cosma S.p.A. (IT) 2020-02-19 EP claimed
WO-2018188763-A1 NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB COSMA S.P.A. (IT) 2018-10-18 WO claimed
CN-110914250-B Novel process for synthesizing tilobaxib 珂思玛股份公司 2023-06-27 CN disclosed
CN-110914250-B Novel process for synthesizing tilobaxib 珂思玛股份公司 2023-06-27 CN disclosed
EP-3609877-B1 PROCESS FOR THE SYNTHESIS OF FIROCOXIB COSMA S P A (IT) 2020-12-23 EP disclosed
US-10807962-B2 Process for the synthesis of firocoxib COSMA S.P.A. (IT) 2020-10-20 US disclosed
US-10807962-B2 Process for the synthesis of firocoxib COSMA S.P.A. (IT) 2020-10-20 US disclosed
US-20200102279-A1 NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB COSMA S.P.A. (IT) 2020-04-02 US disclosed
US-20200102279-A1 NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB COSMA S.P.A. (IT) 2020-04-02 US disclosed
CN-110914250-A Novel process for synthesizing felicoxib 珂思玛股份公司 2020-03-24 CN disclosed
CN-110914250-A Novel process for synthesizing felicoxib 珂思玛股份公司 2020-03-24 CN disclosed
EP-3609877-A1 NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB Cosma S.p.A. (IT) 2020-02-19 EP disclosed
EP-3609877-A1 NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB Cosma S.p.A. (IT) 2020-02-19 EP disclosed
WO-2018188763-A1 NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB COSMA S.P.A. (IT) 2018-10-18 WO disclosed
WO-2018188763-A1 NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB COSMA S.P.A. (IT) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102279-A1 NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB PPOX, RIOX2, CYP4X1 PLK1 2117/4885LMNA 3044/4885HPGD 277/4885
US-10807962-B2 Process for the synthesis of firocoxib RIOX2, PPOX, CYP4X1 PLK1 1792/4885LMNA 2851/4885HPGD 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.